<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alprostadil: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alprostadil: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Alprostadil: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11212" href="/d/html/11212.html" rel="external">see "Alprostadil: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13353" href="/d/html/13353.html" rel="external">see "Alprostadil: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708622"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Apnea (Prostin VR Pediatric): </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Apnea is experienced by about 10% to 12% of neonates with congenital heart defects treated with alprostadil pediatric sterile solution. Apnea is most often seen in neonates weighing less than 2 kg at birth and usually appears during the first hour of drug infusion. Therefore, monitor respiratory status throughout treatment, and use alprostadil pediatric injection where ventilatory assistance is immediately available.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F132167"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Caverject;</li>
<li>Caverject Impulse;</li>
<li>Edex;</li>
<li>Muse;</li>
<li>Prostin VR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865618"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Caverject;</li>
<li>Muse;</li>
<li>Prostin VR</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F132207"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Prostaglandin;</li>
<li>
                        Vasodilator</li></ul></div>
<div class="block doa drugH1Div" id="F132171"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="77b945d9-a93d-48b1-8ab3-46e494efb128">Erectile dysfunction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erectile dysfunction, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intracavernous (Caverject, Caverject Impulse, Edex): </b>Individualize dose by careful titration; doses &gt;40 mcg (Edex) or &gt;60 mcg (Caverject) are not recommended: Initial dose must be titrated in health care provider setting. Patient must stay in the health care setting until complete detumescence occurs; if there is no response, then the next higher dose may be given within 1 hour; if there is still no response, a 1-day interval before giving the next dose is recommended; doses should be titrated to the lowest effective dose; increasing the dose or concentration in the treatment of impotence results in increasing pain and discomfort.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial dose titration: According to the prescribing information for Caverject and Caverject Impulse, no more than 2 doses should be given within a 24-hour period during the initial titration.</p>
<p style="text-indent:-2em;margin-left:8em;">Vasculogenic, psychogenic, or mixed etiology: Initiate dosage titration at 2.5 mcg.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>If there is a partial response</i>, administer another dose of 2.5 mcg within 1 hour; if additional titration is needed, administer doses in increments of 5 to 10 mcg at least 24 hours apart (depending on erectile response) until the dose that produces an erection suitable for intercourse and not exceeding a duration of 1 hour is reached.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>If there is no response</i> to the initial 2.5 mcg dose, the second dose may be increased to 7.5 mcg and administered within 1 hour, followed by increments of 5 to 10 mcg (Edex).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>If there is a response</i>, then there should be at least a 24-hour interval before the next dose is given.</p>
<p style="text-indent:-2em;margin-left:8em;">Neurogenic etiology (eg, spinal cord injury): <b>Note:</b> Caverject powder must be used to prepare a 1.25 mcg dose: Initiate dosage titration at 1.25 mcg; if there is a partial response, administer another dose of 1.25 mcg within 1 hour; if additional titration is needed, administer a dose of 5 mcg at least 24 hours later. Repeat the titration as needed until an optimal dose is reached that produces an erection suitable for intercourse and not exceeding a duration of 1 hour.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Once an appropriate dose has been determined, patient may self-administer injections at a frequency of no more than 3 times/week with at least 24 hours between doses; reevaluate every 3 months (or as clinically appropriate) to determine if dosage adjustments are needed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intraurethral (Muse Pellet): </b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 125 to 250 mcg; dose may be increased or decreased on separate occasions in a stepwise manner until the patient achieves an erection that is sufficient for sexual intercourse.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Administer as needed to achieve an erection; duration of action is about 30 to 60 minutes; use only two systems per 24-hour period.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Erectile dysfunction, adjunct to the diagnosis of (Caverject, Caverject Impulse): Intracavernous:</b> As an adjunct to laboratory tests (eg, duplex or Doppler ultrasound), administer a single dose that induces a rigid erection; see vasculogenic, psychogenic, or mixed etiology dosage regimen.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fed0e48d-298d-453f-bda8-97189c608a2d">Raynaud phenomenon</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Raynaud phenomenon, refractory or digital ischemia (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use in patients who have suboptimal response to first-line oral therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10479851','lexi-content-ref-27941129','lexi-content-ref-11327251','lexi-content-ref-15370722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10479851','lexi-content-ref-27941129','lexi-content-ref-11327251','lexi-content-ref-15370722'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 60 mcg over 3 hours once daily for 5 or 6 consecutive days; may repeat this same regimen at 6-week intervals <b>or</b> may administer a maintenance dose of 60 mcg over 3 hours once every 30 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10479851','lexi-content-ref-11327251','lexi-content-ref-15370722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10479851','lexi-content-ref-11327251','lexi-content-ref-15370722'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjust</b>
<b>ment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991169"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988552"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F132172"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Use lowest effective dose. In clinical studies with Edex, higher minimally effective doses and a higher rate of lack of effect were noted. Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F132189"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13353" href="/d/html/13353.html" rel="external">see "Alprostadil: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e4e36a9a-84e1-4db6-bb39-4ad74e43b004">Ductus arteriosus patency, maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ductus arteriosus patency, maintenance</b>: Infants: Continuous IV infusion: Initial: 0.05 to 0.1 mcg/kg/minute; once therapeutic response is achieved, reduce rate to lowest effective dosage; with unsatisfactory response, increase rate gradually; usual maintenance: 0.01 to 0.4 mcg/kg/minute.<b> Note:</b> Therapeutic response is indicated by an increase in systemic blood pressure and pH in those with restricted systemic blood flow and acidosis, or by an increase in oxygenation (pO<sub>2</sub>) in those with restricted pulmonary blood flow.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51064606"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51064607"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F132136"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraurethral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%: Genitourinary: Penile pain, urethral burning</p>
<p style="text-indent:-2em;margin-left:4em;">2% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Central nervous system: Dizziness, headache, pain</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Testicular pain, urethral bleeding (minor), vulvovaginal pruritus (female partner)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;2%: Leg pain, perineal pain, tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracavernosal injection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%: Genitourinary: Penile pain</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Hypertension</p>
<p style="text-indent:-2em;margin-left:6em;">Central nervous system: Dizziness, headache</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Prolonged erection (&gt;4 hours, 4%), penile disease, penile rash, penile swelling, Peyronie's disease</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Bruising at injection site, hematoma at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%: Balanitis, injection site hemorrhage, priapism (0.4%)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravenous:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Flushing</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Apnea</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Bradycardia, cardiac arrest, edema, hypertension, hypotension, tachycardia</p>
<p style="text-indent:-2em;margin-left:6em;">Central nervous system: Dizziness, headache, seizure</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hypokalemia</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Diarrhea</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Sepsis</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Local pain (in structures other than the injection site)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Back pain</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Cough, flu-like symptoms, nasal congestion, sinusitis, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%: Anemia, anuria, bradypnea, cardiac failure, cerebral hemorrhage, gastroesophageal reflux disease, hematuria, hemorrhage, hyperbilirubinemia, hyperemia, hyperirritability, hyperkalemia, hypoglycemia, hypothermia, jitteriness, lethargy, neck hyperextension, peritonitis, second degree atrioventricular block, shock, stiffness, supraventricular tachycardia, thrombocytopenia, ventricular fibrillation, wheezing (bronchial)</p></div>
<div class="block coi drugH1Div" id="F132150"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Intracavernous: Hypersensitivity to alprostadil or any component of the formulation; conditions predisposing men to priapism (eg, sickle cell anemia or trait, multiple myeloma, leukemia); men with anatomical deformation or fibrotic conditions of the penis (eg, angulation, cavernosal fibrosis, or Peyronie disease); penile implants</p>
<p style="text-indent:-2em;margin-left:2em;">IV: There are no contraindications listed in the US labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling</i>: Cyanotic neonates with persistent circulation; neonates with total anomalous pulmonary venous return below the diaphragm; neonates with polysplenia or asplenia in whom pulmonary atresia is combined with anomalous pulmonary venous return, which may be obstructed</p>
<p style="text-indent:-2em;margin-left:2em;">Transurethral: Hypersensitivity to alprostadil or any component of the formulation; urethral stricture, balanitis, severe hypospadias and curvature, and in men with acute or chronic urethritis; men who are prone to venous thrombosis or who have a hyperviscosity syndrome (eg, sickle cell anemia or trait, thrombocythemia, polycythemia, multiple myeloma) predisposing them to priapism; use in men for whom sexual activity is inadvisable; sexual intercourse with a pregnant woman unless a condom barrier is being used</p></div>
<div class="block war drugH1Div" id="F132133"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Apnea: <b>[US Boxed Warning]: Prostin VR Pediatric: Apnea may occur in 10% to 12% of neonates with congenital heart defects, especially in those weighing &lt;2 kg at birth.</b> Apnea usually appears during the first hour of drug infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension/syncope: Intracavernous injections can increase peripheral blood levels of alprostadil, resulting in hypotension. Syncope has also been reported. Avoid use in men with known cavernosal venous leakage. Patients must be cautioned to avoid tasks such as operating machinery or driving following administration where injury could result if hypotension or syncope were to occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Penile fibrosis: May occur when used for erectile dysfunction; discontinue use in men who develop penile angulation or cavernosal fibrosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Priapism/prolonged erection: May occur when used for erectile dysfunction; instruct patient to seek immediate medical assistance if an erection persists ≥4 hours; discontinue therapy if priapism or prolonged erection occurs or if signs of penile fibrosis develop (penile angulation, cavernosal fibrosis, or Peyronie disease). To minimize the chances of prolonged erection or priapism, titrate slowly to the lowest effective dose. Use is contraindicated in men who have conditions that predispose them to priapism (eg, sickle cell anemia or trait, multiple myeloma, leukemia). Underlying causes of erectile dysfunction should be evaluated and treated prior to therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Treatment for erectile dysfunction should not be used in men whom sexual activity is inadvisable because of underlying cardiovascular status.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: Prostin VR Pediatric: Use with caution in neonates with bleeding tendencies.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Muse: Urethral abrasion resulting in minor bleeding or spotting may occur from improper administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Needle breakage: Caverject and Caverject Impulse: A superfine needle is used for administration. Needle breakage (a portion of the needle remaining in the penis) has been reported; hospitalization and surgical removal may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patency of ductus arteriosus: Appropriate use: Prostin VR Pediatric: Infuse for the shortest time at the lowest dose consistent with good patient care. Use for &gt;120 hours has been associated with antral hyperplasia and gastric outlet obstruction.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878319"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Alprostadil should not be used in neonates with respiratory distress syndrome; full diagnostic workup should be done to differentiate between respiratory distress syndrome and cyanotic heart disease. Cortical proliferation of long bones has been associated with long-term infusions of alprostadil; most cases of bone changes occurred 4 to 6 weeks after starting alprostadil, but has occurred as early as 9 days. In a study of 86 infants awaiting cardiac transplant, the incidence of hyperostosis was 42% at &lt;30 days of alprostadil infusion, 87% at 30 to 60 days and 100% at &gt;60 days. Cortical hyperostosis usually resolves over 6 to 12 months after stopping alprostadil (Kaufman 1996; Woo 1994).</p></div>
<div class="block foc drugH1Div" id="F132144"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intracavernosal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Caverject Impulse: 10 mcg, 20 mcg [contains benzyl alcohol, lactose]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Edex: 10 mcg, 20 mcg, 40 mcg [pyrogen free; contains lactose]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Pellet, Urethral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Muse: 125 mcg (1 ea [DSC], 6 ea [DSC]); 250 mcg (1 ea, 6 ea); 500 mcg (1 ea, 6 ea); 1000 mcg (1 ea, 6 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prostin VR: 500 mcg/mL (1 mL) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mcg/mL (1 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intracavernosal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Caverject: 40 mcg (1 ea) [contains benzyl alcohol, lactose]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intracavernosal [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Caverject: 20 mcg (1 ea) [contains lactose]</p></div>
<div class="block geq drugH1Div" id="F132129"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F132152"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Caverject Impulse Intracavernosal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mcg (per each): $98.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mcg (per each): $126.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Edex Intracavernosal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mcg (per each): $204.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mcg (per each): $264.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mcg (per each): $360.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pellet</b> (Muse Urethral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mcg (per each): $81.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mcg (per each): $87.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mcg (per each): $94.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Prostin VR Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mcg/mL (per mL): $175.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Caverject Intracavernosal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mcg (per each): $126.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mcg (per each): $166.22</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865619"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intracavernosal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Caverject: 20 mcg [contains benzyl alcohol, lactose]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Pellet, Urethral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Muse: 250 mcg (1 ea); 500 mcg (1 ea); 1000 mcg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prostin VR: 500 mcg/mL (1 mL) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intracavernosal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Caverject: 20 mcg (1 ea) [contains lactose]</p></div>
<div class="block adm drugH1Div" id="F132147"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracavernous:</b> Erectile dysfunction:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Caverject:</i> Wipe the intended injection site with an alcohol swab prior to injection. Use a <sup>1</sup>/<sub>2</sub> inch, 29- or 30-gauge needle. Inject into the dorsolateral aspect of the proximal third of the penis, avoiding visible veins; alternate side of the penis for injections. Compress the site of injection with an alcohol swab or sterile gauze for 5 minutes after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Caverject Impulse:</i> Supplied as a disposable, single-dose, dual chamber syringe system. Wipe the intended injection site with an alcohol swab prior to injection. After attaching the provided needle assembly, select dose and inject into the dorsolateral aspect of the proximal third of the penis, avoiding visible veins; alternate side of the penis for injections. Compress the site of injection with an alcohol swab or sterile gauze for 5 minutes after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Edex:</i> Wipe the intended injection site with an alcohol swab prior to injection. Use a <sup>1</sup>/<sub>2</sub> inch, 27- to 30-gauge needle. Inject into the dorsolateral aspect of the proximal third of the penis, avoiding visible veins; alternate side of the penis for injections. Administer over a 5- to 10-second interval. Compress the site of injection with an alcohol swab for 5 minutes after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraurethral:</b> Erectile dysfunction:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Muse:</i> Insert immediately after urination. Prior to insertion, remove the product from the foil pouch and remove the protective cover from the applicator stem; ensure medicated pellet is present. While sitting or standing, slowly stretch the penis upward to its full length, with gentle compression from top to bottom of the glans. Slowly insert the Muse stem into the urethra up to the collar. Gently press down on the button at the top of the applicator until it stops; leave applicator in place for 5 seconds. Gently rock the applicator from side to side then remove the applicator while keeping the penis upright. If there is residual medication at the end of the applicator, reinsert the applicator and repeat prior steps. Once the applicator is removed, hold the penis upright and stretched to its full length, and roll firmly between hands for at least 10 seconds. Standing or walking for about 10 minutes after administration will increase blood flow and enhance erection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Raynaud phenomenon, refractory or digital ischemia (off-label use): Dilute dose in 250 mL of NS or D5W. Administer 60 mcg over ~3 hours through a peripheral vein (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10479851','lexi-content-ref-11327251','lexi-content-ref-15370722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10479851','lexi-content-ref-11327251','lexi-content-ref-15370722'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612204"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Continuous IV infusion: Administer into a large vein or alternatively through an umbilical artery catheter placed at the ductal opening.</p>
<p style="text-indent:0em;margin-left:2em;margin-top:2em;">Rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by concentration (mcg/mL)</p></div>
<div class="block uicp drugH1Div" id="F14471275"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 5 mcg/mL, 10 mcg/mL, <b>or</b> 20 mcg/mL.</p></div>
<div class="block use drugH1Div" id="F132146"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Patent ductus arteriosus (Prostin VR Pediatric):</b> Temporary maintenance of patency of ductus arteriosus in neonates with ductal-dependent congenital heart disease until surgery can be performed. These defects include cyanotic (eg, pulmonary atresia, pulmonary stenosis, tricuspid atresia, Fallot's tetralogy, transposition of the great vessels) and acyanotic (eg, interruption of aortic arch, coarctation of aorta, hypoplastic left ventricle) heart disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Erectile dysfunction:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Caverject, Edex, Caverject Impulse:</b> Treatment of erectile dysfunction due to vasculogenic, psychogenic, neurogenic, or mixed etiology; Caverject and Caverject Impulse may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Muse:</b> Treatment of erectile dysfunction</p></div>
<div class="block off-label drugH1Div" id="F25720652"><span class="drugH1">Use: Off-Label: Adult</span><p>Raynaud phenomenon, refractory or digital ischemia</p></div>
<div class="block mst drugH1Div" id="F132214"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Alprostadil may be confused with alPRAZolam</p>
<p style="text-indent:-2em;margin-left:4em;">Prostin VR may be confused with Prostin E2 (dinoprostone)</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298715"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F132138"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Landiolol: Alprostadil may diminish the therapeutic effect of Landiolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of Alprostadil.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53510662"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Muse is contraindicated in males having sexual intercourse with a pregnant woman unless a condom barrier is being used.</p></div>
<div class="block pri drugH1Div" id="F132153"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Alprostadil is not indicated for use in women.</p></div>
<div class="block brc drugH1Div" id="F20520330"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Alprostadil is not indicated for use in women.</p></div>
<div class="block mop drugH1Div" id="F132142"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Blood pressure, respiratory rate, heart rate, temperature, degree of penile pain, duration of erection, adequate detumescence after dosing, signs of infection, signs of penile fibrosis.</p>
<p style="text-indent:-2em;margin-left:2em;">Raynaud phenomenon: Vasospasm frequency and duration.</p>
<p style="text-indent:-2em;margin-left:2em;">Ductus arteriosus patency: Blood pressure, respiratory rate, heart rate, temperature, pO<sub>2</sub>; signs and symptoms of apnea and necrotizing enterocolitis (Akkinapally 2018). With prolonged administration (&gt;120 hours), monitor for gastric outlet obstruction, cortical hyperostosis, and brown fat necrosis; x-rays may be needed to assess cortical hyperostosis (Akkinapally 2018).</p></div>
<div class="block pha drugH1Div" id="F132132"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Causes vasodilation by means of direct effect on vascular and ductus arteriosus smooth muscle; relaxes trabecular smooth muscle and dilates cavernosal arteries when injected along the penile shaft, allowing blood flow to and entrapment in the lacunar spaces of the penis (ie, corporeal veno-occlusive mechanism)</p></div>
<div class="block phk drugH1Div" id="F132149"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Erectile dysfunction: 5 to 20 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Ductus arteriosus will begin to close within 1 to 2 hours after drug is stopped; Erectile dysfunction: Intended duration &lt;1 hour</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Insignificant following penile injection </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding, plasma: 81% to albumin </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: IV: ~70% to 80% by oxidation during a single pass through the lungs; metabolite (13,14 dihydro-PGE<sub>1</sub>) is active and has been identified in neonates </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 30 seconds to 10 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acyanotic congenital heart disease: Usual: 1.5 to 3 hours; Range: 15 minutes to 11 hours.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cyanotic congenital heart disease: Usual: ~30 minutes</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Erectile dysfunction: Intracavernosal 30 to 60 minutes; Transurethral: ~16 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily urine (90% as metabolites) within 24 hours; feces</p></div>
<div class="block phksp drugH1Div" id="F51220160"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pulmonary disease: May have reduced capacity to clear the drug.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F132154"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse | Prostin vr | Vitaros</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cardiobron | Caverject | Muse | Prostavasin | Vitaros</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse | Prostavasin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Vytaros</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Prostavasin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Aplicav | Caverject | Muse | Prostavasin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Vitaros</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bi fa er | Bo le si | Caverject | Fo er shu | Kai shi | Prostaglandin e1 | Prostavasin | Pu kang xi | Pu si tai | Qi nuo ning | Sai er | You di er</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cardiobron | Caverject | Dalveol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Prostavasin | Vitaros</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Caverject impuls | Muse | Prostavasin | Viridal | Vitaros</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Caverject</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse | Vasostenoon | Viridal</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Prostavasin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alprostadil genfarma | Caverject | Muse | Virirec</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse | Rigidur | Vitaros</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Alprostadil intsel chimos | Alprostadil panpharma | Caverject | Caverjectdual | Edex | Muse | Vitaros</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse | Viridal | Viridal duo | Vitaros</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Edex | Prostin vr | Vitaros</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Befar | Caverject | Muse</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Alprostadil altan | Caverject | Prostavasin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Caverject</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse | Viridal | Vitaros</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Alprostapint | Caverject | Muse</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Prostacel | Prostal</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse | Prostavasin | Viridal | Vitaros</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Prostavasin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Altesil | Alyprost | Alyprost chemiphar | Apistandin | Ipceryl | Mediprost | Prink | Prink taiyo | Prostandin | Tandetron | Tandetron yamakawa</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alproalpha | Alprodex | Befar | Caverject | Dong a prostandin | Muse | Prostandin | Stensuh</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse | Prostavasin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Vitaros</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Prostavasin | Vasaprostan | Vazaprostan | Vitaros</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Prostavasin | Vytaros</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Prostavasin | Vasostenoon | Vazaprostan | Vitaros</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Caverject</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse | Prostavasin | Vitaros</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse | Vitaros</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bondil | Caverject | Caverject impuls | Muse | Vitaros</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Caverject</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Prostavasin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Prostavasin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Prostavasin | Prostin vr | Vytaros</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Edex | Muse</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse | Vasoprost | Vitaros</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Alprostadil quimfa</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Prostin VR</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Alprostadil pint | Alprostadil rompharm | Vasaprostan | Vitaros</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Arteris vero | Caverject | Coverject | Edex | Prostavasin | Prostin vr | Vazaprostan</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse | Vitaros</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bondil | Caverject | Rigidur | Rigidur Duo | Virilan | Vitaros</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Muse</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Caverject</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Prostavasin | Vitaros</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Caverject | Prostin vr</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Caverject</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Jectera</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alprosm | Caverject | Promostan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Albioprostadil | Caverject | Edex | Vazaprostan</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cardiobron | Caverject</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Caverject</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Muse</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Caverject</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26534956">
<a name="26534956"></a>Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association (AHA) and American Thoracic Society (ATS). <i>Circulation</i>. 2015;132(21):2037-2099. doi:10.1161/CIR.0000000000000329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/26534956/pubmed" id="26534956" target="_blank">26534956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29486048">
<a name="29486048"></a>Akkinapally S, Hundalani SG, Kulkarni M, et al. Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions. <i>Cochrane Database Syst Rev</i>. 2018;2(2):CD011417. doi:10.1002/14651858.CD011417.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/29486048/pubmed" id="29486048" target="_blank">29486048</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Alprostadil [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated August 2022. Accessed April 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10479851">
<a name="10479851"></a>Bartolone S, Trifiletti A, De Nuzzo G, et al. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon. <i>Minerva Cardioangiol</i>. 1999;47(5):137-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/10479851/pubmed" id="10479851" target="_blank">10479851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16567166">
<a name="16567166"></a>Buss M, Williams G, Dilley A, Jones O. Prevention of heart failure in the management of congenital diaphragmatic hernia by maintaining ductal patency. A case report. <i>J Pediatr Surg</i>. 2006;41(4):e9-e11. doi:10.1016/j.jpedsurg.2006.01.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/16567166/pubmed" id="16567166" target="_blank">16567166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.1">
<a name="Pfizer.1"></a>Caverject (alprostadil) [prescribing information]. New York, NY: Pfizer Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.2">
<a name="Pfizer.2"></a>Caverject Impulse (alprostadil) [prescribing information]. New York, NY: Pfizer Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol-United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17687059">
<a name="17687059"></a>Cohen V, Jellinek SP, Teperikidis L, et al, “Room-Temperature Storage of Medications Labeled for Refrigeration,” <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/17687059/pubmed" id="17687059" target="_blank">17687059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34952853">
<a name="34952853"></a>De Bie FR, Avitabile CM, Joyeux L, et al. Neonatal and fetal therapy of congenital diaphragmatic hernia-related pulmonary hypertension. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2022;107(5):458-466. doi:10.1136/archdischild-2021-322617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/34952853/pubmed" id="34952853" target="_blank">34952853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Divekar.1">
<a name="Divekar.1"></a>Divekar A, Seshia MM, Kesselman M. Non-restrictive ductal patency in management of cardiac failure in congenital diaphragmatic hernia – non-invasive biventricular assist. <i>J Neonatal Biol</i>. 2015;4(2). doi:10.4172/2167-0897.1000171</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Actient.1">
<a name="Actient.1"></a>Edex (alprostadil) [prescribing information]. Lake Forest, IL: Actient Pharmaceuticals; August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16630327">
<a name="16630327"></a>Filan PM, McDougall PN, Shekerdemian LS. Combination pharmacotherapy for severe neonatal pulmonary hypertension. <i>J Paediatr Child Health</i>. 2006;42(4):219-220. doi:10.1111/j.1440-1754.2006.00835.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/16630327/pubmed" id="16630327" target="_blank">16630327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11327251">
<a name="11327251"></a>Gardinali M, Pozzi MR, Bernareggi M, et al. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. <i>J Rheumatol</i>. 2001;28(4):786-794.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/11327251/pubmed" id="11327251" target="_blank">11327251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35844758">
<a name="35844758"></a>Hari Gopal S, Patel N, Fernandes CJ. Use of prostaglandin E1 in the management of congenital diaphragmatic hernia-a review. <i>Front Pediatr</i>. 2022;10:911588. doi:10.3389/fped.2022.911588<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/35844758/pubmed" id="35844758" target="_blank">35844758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36538050">
<a name="36538050"></a>Haughey BS, Elliott MR, Wiggin JY, et al. Standardizing prostaglandin initiation in prenatally diagnosed ductal-dependent neonates; a quality initiative. <i>Pediatr Cardiol</i>. 2023;44(6):1327-1332. doi:10.1007/s00246-022-03075-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/36538050/pubmed" id="36538050" target="_blank">36538050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, “Standard Concentrations of Neonatal Drug Infusions,” 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8833563">
<a name="8833563"></a>Kaufman MB and El-Chaar GM, “Bone and Tissue Changes Following Prostaglandin Therapy in Neonates,” <i>Ann Pharmacother</i>, 1996, 30(3):269-74, 277.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/8833563/pubmed" id="8833563" target="_blank">8833563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann Rheum Dis</i>. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30442461">
<a name="30442461"></a>Lawrence KM, Berger K, Herkert L, et al. Use of prostaglandin E1 to treat pulmonary hypertension in congenital diaphragmatic hernia. <i>J Pediatr Surg</i>. 2019;54(1):55-59. doi:10.1016/j.jpedsurg.2018.10.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/30442461/pubmed" id="30442461" target="_blank">30442461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32061366">
<a name="32061366"></a>Le Duc K, Mur S, Sharma D, et al. Prostaglandin E1 in infants with congenital diaphragmatic hernia (CDH) and life-threatening pulmonary hypertension. <i>J Pediatr Surg</i>. 2020;55(9):1872-1878. doi:10.1016/j.jpedsurg.2020.01.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/32061366/pubmed" id="32061366" target="_blank">32061366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7285304">
<a name="7285304"></a>Lewis AB, Freed MD, Heymann MA, et al, “Side Effects of Therapy With Prostaglandin E<sub>1</sub> in Infants With Critical Congenital Heart Disease,” <i>Circulation</i>, 1981, 64(5):893-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/7285304/pubmed" id="7285304" target="_blank">7285304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15370722">
<a name="15370722"></a>Marasini B, Massarotti M, Bottasso B, et al. Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon. <i>Scand J Rheumatol</i>. 2004;33(4):253-256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/15370722/pubmed" id="15370722" target="_blank">15370722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meda.1">
<a name="Meda.1"></a>Muse (alprostadil) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1635565">
<a name="1635565"></a>Peled N, Dagan O, Babyn P, et al, “Gastric-Outlet Obstruction Induced by Prostaglandin Therapy in Neonates,” <i>N Engl J Med</i>, 1992, 327(8):505-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/1635565/pubmed" id="1635565" target="_blank">1635565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058104">
<a name="22058104"></a>Phillips MS, “Standardizing I.V. Infusion Concentrations: National Survey Results,” <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/22058104/pubmed" id="22058104" target="_blank">22058104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.3">
<a name="Pfizer.3"></a>Prostin VR (alprostadil) sterile solution [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.4">
<a name="Pfizer.4"></a>Prostin VR Pediatric (alprostadil injection) [prescribing information]. New York, NY: Pfizer Injectables; April 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pharmacia.1">
<a name="Pharmacia.1"></a>Prostin VR Pediatric (alprostadil) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; July 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18726605">
<a name="18726605"></a>Shiyanagi S, Okazaki T, Shoji H, et al. Management of pulmonary hypertension in congenital diaphragmatic hernia: nitric oxide with prostaglandin-E1 versus nitric oxide alone. <i>Pediatr Surg Int</i>. 2008;24(10):1101-1104. doi:10.1007/s00383-008-2225-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/18726605/pubmed" id="18726605" target="_blank">18726605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16565906">
<a name="16565906"></a>Stone DM, Frattarelli DA, Karthikeyan S, et al, "Altered Prostaglandin E1 Dosage During Extracorporeal Membrane Oxygenation in a Newborn With Ductal-Dependent Congenital Heart Disease," <i>Pediatr Cardiol</i>, 2006, 27(3):360-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/16565906/pubmed" id="16565906" target="_blank">16565906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33140712">
<a name="33140712"></a>Vari D, Xiao W, Behere S, Spurrier E, Tsuda T, Baffa JM. Low-dose prostaglandin E1 is safe and effective for critical congenital heart disease: is it time to revisit the dosing guidelines? <i>Cardiol Young</i>. 2021;31(1):63-70. doi:10.1017/S1047951120003297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/33140712/pubmed" id="33140712" target="_blank">33140712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VON.1">
<a name="VON.1"></a>Vermont Oxford Network (VON). Neonatal drug concentrations. https://public.vtoxford.org/wp-content/uploads/2022/11/Neonatal-Drug-Concentrations-Updated-November-2022.pdf. Updated November 2022. Accessed July 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1913785">
<a name="1913785"></a>Weesner KM, “Hemodynamic Effects of Prostaglandin E<sub>1</sub> in Patients With Congenital Heart Disease and Pulmonary Hypertension,” <i>Cathet Cardiovasc Diagn</i>, 1991, 24(1):10-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/1913785/pubmed" id="1913785" target="_blank">1913785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9883223">
<a name="9883223"></a>Williams G, Abbou CC, Amar ET, et al, “The Effect of Transurethral Alprostadil on the Quality of Life of Men With Erectile Dysfunction, and Their Partners. MUSE Study Group,” <i>Br J Urol</i>, 1998, 82(6):847-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/9883223/pubmed" id="9883223" target="_blank">9883223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8115200">
<a name="8115200"></a>Woo K, Emery J, and Peabody J, “Cortical Hyperostosis: A Complication of Prolonged Prostaglandin Infusion in Infants Awaiting Cardiac Transplantation,” <i>Pediatrics</i>, 1994, 93(3):417-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/8115200/pubmed" id="8115200" target="_blank">8115200</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8459 Version 269.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
